1141 KB25 KB202120242022Krivec, Štefkaštevilka:4str. 25-33COBISSID:127221763ISSN:2670-4463URN:URN:NBN:SI:doc-138KALJUslSlovensko združenje za klinično kemijo in laboratorijsko medicinoLaboratorijska medicinaDislipidemijeDyslipidemiasLipoproteiniLipoproteinsNovejša spoznanja na področju presnove lipoproteinov| Recent advances in lipoprotein metabolism|Cardiovascular diseases are still the leading cause of death in the world. There are many risk factors for their development; one of the most important is dyslipidemia (increased or decreased lipoprotein levels). Dyslipidemias can be caused by certain diseases (secondary), but most often they are due to the interaction of genetic and environmental factors (primary). The paper describes lipoprotein metabolism pathways involving a number of lipoprotein receptors, membrane transporters, enzymes, and transport proteins. We have known many of them for a long time, but new ones are being discovered. Understanding the molecular and genetic mechanisms of lipoprotein metabolism is the basis for exploring the pathophysiology of dyslipidemias and has important clinical applications. New drugs are being developed that can be used in combination with statins to lower serum LDL-cholesterol and further reduce the risk of cardiovascular disease (the case of the PCSK9 inhibitor). Greater knowledge of lipoprotein metabolism will in the future open possibilities for targeted individualized treatment of dyslipidemiasSrčno-žilne bolezni so v svetu še vedno glavni vzrok smrtnosti. Dejavnikov tveganja za njihov razvoj je mnogo; eden pomembnejših so dislipidemije (zvišane ali znižane vrednosti lipoproteinov). Dislipidemije so lahko posledica nekaterih obolenj (sekundarne), največkrat pa so posledica medsebojnega delovanja genetskih in okoljskih dejavnikov (primarne). V članku so opisane poti presnove lipoproteinov, v katere so vključeni številni lipoproteinski receptorji, membranski transporterji, encimi in transportni proteini. Mnoge od njih poznamo že dolgo, odkrivajo pa se novi. Razumevanje molekularnih in genetskih mehanizmov presnove lipoproteinov je osnova za raziskovanje patofiziologije dislipidemij in ima pomembno klinično uporabnost. Razvijajo se nova zdravila, ki se lahko uporabljajo v kombinaciji s statini za nižanje serumskega LDL-holesterola in nadaljnje zmanjševanje tveganja za srčno-žilne bolezni (primer inhibitorja PCSK9). Večje poznavanje presnove lipoproteinov bo v prihodnosti odprlo možnosti za ciljano, posamezniku prilagojeno zdravljenje dislipidemijTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of Slovenia